Ultragenyx Pharmaceutical Inc.
GPTKB entity
Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Emil_D._Kakkis
|
| gptkbp:collaboratedWith |
gptkb:Kyowa_Kirin
gptkb:Regeneron_Pharmaceuticals GeneTx Biotherapeutics |
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focus |
rare diseases
|
| gptkbp:founded |
2010
|
| gptkbp:founder |
gptkb:Emil_D._Kakkis
|
| gptkbp:headquartersLocation |
gptkb:Novato,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Ultragenyx Pharmaceutical Inc.
|
| gptkbp:industry |
gptkb:biotechnology
pharmaceuticals |
| gptkbp:marketCap |
multi-billion USD (as of 2023)
|
| gptkbp:notableEmployee |
gptkb:Emil_D._Kakkis
|
| gptkbp:numberOfEmployees |
over 1000
|
| gptkbp:product |
gptkb:Crysvita
gptkb:Dojolvi gptkb:Evkeeza gptkb:Mepsevii |
| gptkbp:publiclyTraded |
true
|
| gptkbp:specialty |
development of novel products for rare and ultra-rare genetic diseases
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
RARE
|
| gptkbp:website |
https://www.ultragenyx.com/
|
| gptkbp:bfsParent |
gptkb:NASDAQ:_RARE
|
| gptkbp:bfsLayer |
8
|